Health Economics›Non-clear cell renal cell carcinoma›Metastatic disease first-line

Metastatic disease first-line

Non-clear cell renal cell carcinoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~4.7 mo	~11.5 mo	~11	~R 3 156 508 PFS proxy · indirect	5
Sunitinib monotherapy Variant #05	—	R 33 433	28d	8.3 mo	—	10	R 334 331 PFS proxy	1
Everolimus monotherapy Variant #01	—	R 18 360	28d	~5.6 mo	~17.6 mo	~7	~R 128 518 PFS proxy · indirect	11

3 of 3 regimens shown